Fabrazyme Patient, Information, Instructions - Agalsidase Beta

Fabrazyme Patient, Information, Instructions - Agalsidase Beta

PATIENT INFORMATION

Patients should be informed that a Registry has been established in order to better understand the variability and progression of Fabry disease in the population as a whole and in women, and to monitor and evaluate long-term treatment effects of Fabrazyme^®. The Registry will also monitor the effect of Fabrazyme^® on pregnant women and their offspring, and determine if Fabrazyme^Ò is excreted in breast milk. Patients should be encouraged to participate and advised that their participation is voluntary and may involve long-term follow-up. For more information visit www.fabryregistry.com or call (800) 745-4447.

Please also refer to the WARNINGS and PRECAUTIONS sections.